{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T02:01:23Z","timestamp":1785463283023,"version":"3.56.0"},"reference-count":60,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006668","name":"Fondo para la Investigaci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005740","name":"Universidad Nacional del Sur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.xphs.2020.05.027","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T11:22:27Z","timestamp":1591269747000},"page":"2787-2797","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Development of a Carrier-Free Dry Powder Ofloxacin Formulation With Enhanced Aerosolization Properties"],"prefix":"10.1016","volume":"109","author":[{"given":"Nazareth Eliana","family":"Ceschan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melany Denise","family":"Rosas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Eugenia","family":"Olivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea Vanesa","family":"Dugour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Manuel","family":"Figueroa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ver\u00f3nica","family":"Bucal\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ver\u00f3nica","family":"Ram\u00edrez-Rigo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2020.05.027_bib1","series-title":"Controlled Pulmonary Drug Delivery","first-page":"1","article-title":"Macro- and microstructure of the airways for drug delivery","author":"O'Donnell","year":"2011"},{"key":"10.1016\/j.xphs.2020.05.027_bib2","series-title":"Controlled Pulmonary Drug Delivery","first-page":"21","article-title":"Pulmonary drug metabolism, clearance, and absorption","author":"Olsson","year":"2011"},{"key":"10.1016\/j.xphs.2020.05.027_bib3","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijpharm.2012.10.044","article-title":"Chitosan microspheres as an alveolar macrophage delivery system of ofloxacin via pulmonary inhalation","volume":"441","author":"Park","year":"2013","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2020.05.027_bib4","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.tube.2003.08.016","article-title":"Direct lung delivery of para-aminosalicylic acid by aerosol particles","volume":"83","author":"Tsapis","year":"2003","journal-title":"Tuberculosis"},{"key":"10.1016\/j.xphs.2020.05.027_bib5","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ejpb.2015.02.014","article-title":"Barrier or carrier? Pulmonary surfactant and drug delivery","volume":"95","author":"Hidalgo","year":"2015","journal-title":"Eur J Pharm Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2020.05.027_bib6","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1208\/s12249-016-0633-9","article-title":"Formulation and characterization of polysaccharide microparticles for pulmonary delivery of sodium cromoglycate","volume":"8","author":"Gallo","year":"2017","journal-title":"AAPS PharmSciTech"},{"issue":"1","key":"10.1016\/j.xphs.2020.05.027_bib7","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ejps.2007.10.002","article-title":"Interaction between a cationic polymethacrylate (Eudragit E100) and anionic drugs","volume":"33","author":"Quinteros","year":"2008","journal-title":"Eur J Pharm Sci"},{"key":"10.1016\/j.xphs.2020.05.027_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.msec.2016.03.019","article-title":"Polyelectrolyte complex of vancomycin as a nanoantibiotic: preparation, in\u00a0vitro and in silico studies","volume":"63","author":"Sikwal","year":"2016","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.xphs.2020.05.027_bib9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.colsurfb.2011.11.024","article-title":"Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate","volume":"92","author":"Cheow","year":"2012","journal-title":"Colloids Surf B Biointerfaces"},{"key":"10.1016\/j.xphs.2020.05.027_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.powtec.2012.09.023","article-title":"Dry powder inhaler delivery of amorphous drug nanoparticles: effects of the lactose carrier particle shape and size","volume":"233","author":"Kho","year":"2013","journal-title":"Powder Technol"},{"issue":"4","key":"10.1016\/j.xphs.2020.05.027_bib11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.ijantimicag.2005.07.012","article-title":"Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis","volume":"26","author":"Zahoor","year":"2005","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.xphs.2020.05.027_bib12","series-title":"CSRI Conference 2016. Pretoria","first-page":"1","article-title":"Evaluation of nano encapsulation techniques in different polymeric system for the delivery of anti-tuberculosis drugs (ATD)","author":"Swai","year":"2006"},{"key":"10.1016\/j.xphs.2020.05.027_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ijpharm.2014.06.009","article-title":"Fabrication of polyelectrolyte multilayered vesicles as inhalable dry powder for lung administration of rifampicin","volume":"472","author":"Manca","year":"2014","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2020.05.027_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.arbres.2017.02.006","article-title":"Diagnosis and treatment of drug-resistant tuberculosis","volume":"53","author":"Caminero","year":"2017","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.xphs.2020.05.027_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.xphs.2020.05.027_bib16","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1166\/asem.2016.1922","article-title":"Preparation and in\u00a0vitro characterization of albumin nanoparticles encapsulating an anti-tuberculosis drug-levofloxacin","volume":"8","author":"Rather","year":"2016","journal-title":"Adv Sci Eng Med"},{"issue":"2","key":"10.1016\/j.xphs.2020.05.027_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2008.04.009","article-title":"Delivery of ofloxacin to the lung and alveolar macrophages via hyaluronan microspheres for the treatment of tuberculosis","volume":"129","author":"Hwang","year":"2008","journal-title":"J\u00a0Control Release"},{"key":"10.1016\/j.xphs.2020.05.027_bib18","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.msec.2014.04.040","article-title":"New alginic acid-atenolol microparticles for inhalatory drug targeting","volume":"41","author":"Ceschan","year":"2014","journal-title":"Mater Sci Eng C Mater Biol Appl"},{"key":"10.1016\/j.xphs.2020.05.027_bib19","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.powtec.2015.02.001","article-title":"Polymeric microparticles containing indomethacin for inhalatory administration","volume":"285","author":"Ceschan","year":"2015","journal-title":"Powder Technol"},{"key":"10.1016\/j.xphs.2020.05.027_bib20","series-title":"Quality Solutions for Inhaler Testing","year":"2019"},{"key":"10.1016\/j.xphs.2020.05.027_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijpharm.2018.07.065","article-title":"Carrier free indomethacin microparticles for dry powder inhalation","volume":"549","author":"Ceschan","year":"2018","journal-title":"Int J Pharm"},{"key":"10.1016\/j.xphs.2020.05.027_bib22","series-title":"European Pharmacopoeia 7.0.","year":"2010"},{"key":"10.1016\/j.xphs.2020.05.027_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.08.045","article-title":"Influence of size and surface roughness of large lactose carrier particles in dry powder inhaler formulations","volume":"402","author":"Donovan","year":"2010","journal-title":"Int J Pharm"},{"issue":"6","key":"10.1016\/j.xphs.2020.05.027_bib24","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1208\/s12249-014-0176-x","article-title":"Swellable ciprofloxacin-loaded nano-in-micro hydrogel particles for local lung drug delivery","volume":"15","author":"Du","year":"2014","journal-title":"AAPS PharmSciTech"},{"issue":"4","key":"10.1016\/j.xphs.2020.05.027_bib25","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1208\/s12249-014-0126-7","article-title":"In\u00a0Vitro and in\u00a0Vivo performance of dry powder inhalation formulations: comparison of particles prepared by thin film freezing and micronization","volume":"15","author":"Wang","year":"2014","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2020.05.027_bib26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.redox.2018.03.006","article-title":"N-acetyl cysteine reverts the proinflammatory state induced by cigarette smoke extract in lung Calu-3 cells","volume":"16","author":"Valdivieso","year":"2018","journal-title":"Redox Biol"},{"key":"10.1016\/j.xphs.2020.05.027_bib27","series-title":"CellTiter 96\u00ae AQueous Non-radioactive Cell Proliferation Assay","year":"2012"},{"issue":"3","key":"10.1016\/j.xphs.2020.05.027_bib28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1468-3083.2004.01180.x","article-title":"Hyaluronic acid: a unique topical vehicle for the localized delivery of drugs to the skin","volume":"19","author":"Brown","year":"2005","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"6","key":"10.1016\/j.xphs.2020.05.027_bib29","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/mabi.201000388","article-title":"Advances in mucoadhesion and mucoadhesive polymers","volume":"11","author":"Khutoryanskiy","year":"2011","journal-title":"Macromol Biosci"},{"issue":"1-2","key":"10.1016\/j.xphs.2020.05.027_bib30","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.ijpharm.2016.12.002","article-title":"Engineered sodium hyaluronate respirable dry powders for pulmonary drug delivery","volume":"517","author":"Martinelli","year":"2016","journal-title":"Int J Pharm"},{"issue":"5","key":"10.1016\/j.xphs.2020.05.027_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/pharmaceutics11050203","article-title":"Sodium hyaluronate nanocomposite respirable microparticles to tackle antibiotic resistance with potential application in treatment of mycobacterial pulmonary infections","volume":"11","author":"Rossi","year":"2019","journal-title":"Pharmaceutics"},{"issue":"8","key":"10.1016\/j.xphs.2020.05.027_bib32","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1166\/jbn.2015.2091","article-title":"Hyaluronic acid-tocopherol succinate-based self-assembling micelles for targeted delivery of rifampicin to alveolar macrophages","volume":"11","author":"Gao","year":"2014","journal-title":"J\u00a0Biomed Nanotechnol"},{"key":"10.1016\/j.xphs.2020.05.027_bib33","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jconrel.2016.05.064","article-title":"Delivery of LLKKK18 loaded into self-assembling hyaluronic acid nanogel for tuberculosis treatment","volume":"235","author":"Silva","year":"2016","journal-title":"J\u00a0Control Release"},{"issue":"1","key":"10.1016\/j.xphs.2020.05.027_bib34","first-page":"751","article-title":"Hyaluronic acid as an internal phase additive to obtain ofloxacin\/PLGA microsphere by double emulsion method","volume":"24","author":"Wu","year":"2014","journal-title":"Bio Med Mater Eng"},{"issue":"4","key":"10.1016\/j.xphs.2020.05.027_bib35","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ejps.2013.04.023","article-title":"Equilibrium and release properties of hyaluronic acid-drug complexes","volume":"49","author":"Battistini","year":"2013","journal-title":"Eur J Pharm Sci"},{"issue":"21","key":"10.1016\/j.xphs.2020.05.027_bib36","doi-asserted-by":"crossref","first-page":"11896","DOI":"10.1021\/es302097k","article-title":"Surface complexation of the zwitterionic fluoroquinolone antibiotic ofloxacin to nano-anatase TiO2 photocatalyst surfaces","volume":"46","author":"Paul","year":"2012","journal-title":"Environ Sci Technol"},{"key":"10.1016\/j.xphs.2020.05.027_bib37","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0378-5173(90)90130-V","article-title":"Solubilities of some variously quinolone antimicrobials substituted","volume":"63","author":"Ross","year":"1990","journal-title":"Int J Pharm"},{"issue":"10","key":"10.1016\/j.xphs.2020.05.027_bib38","doi-asserted-by":"crossref","first-page":"3788","DOI":"10.1002\/jps.21688","article-title":"Characterization of the solubility and solid-state properties of saccharin salts of fluoroquinolones","volume":"98","author":"Roma\u00f1uk","year":"2009","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.xphs.2020.05.027_bib39","series-title":"Polyelectrolytes, Thermodynamics and Rheology","first-page":"215","article-title":"Thermodynamic and rheological properties of polyelectrolyte systems","author":"Manzo","year":"2014"},{"key":"10.1016\/j.xphs.2020.05.027_bib40","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.molstruc.2013.04.076","article-title":"Spectroscopic, thermal analyses, structural and antibacterial studies on the interaction of some metals with ofloxacin","volume":"1047","author":"Zordok","year":"2013","journal-title":"J\u00a0Mol Struct"},{"key":"10.1016\/j.xphs.2020.05.027_bib41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.carbpol.2011.03.019","article-title":"Chemical modifications of hyaluronic acid for the synthesis of derivatives for a broad range of biomedical applications","volume":"85","author":"Schant\u00e9","year":"2011","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2020.05.027_bib42","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.tifs.2017.03.009","article-title":"Spray-drying of fruit and vegetable juices: effect of drying conditions on the product yield and physical properties","volume":"63","author":"Tontul","year":"2017","journal-title":"Trends Food Sci Technol"},{"issue":"3","key":"10.1016\/j.xphs.2020.05.027_bib43","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0731-7085(02)00682-9","article-title":"Characterization of enzymatically digested hyaluronic acid using NMR, Raman, IR, and UV-Vis spectroscopies","volume":"31","author":"Alkrad","year":"2003","journal-title":"J\u00a0Pharm Biomed Anal"},{"issue":"1-3","key":"10.1016\/j.xphs.2020.05.027_bib44","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.molstruc.2003.11.053","article-title":"Spectroscopic studies on the interaction of ofloxacin with metals","volume":"691","author":"Sagdinc","year":"2004","journal-title":"J\u00a0Mol Struct"},{"issue":"3","key":"10.1016\/j.xphs.2020.05.027_bib45","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.carbpol.2006.01.014","article-title":"Release behavior of microspheres from cross-linked N-methylated chitosan encapsulated ofloxacin","volume":"65","author":"Peng","year":"2006","journal-title":"Carbohydr Polym"},{"key":"10.1016\/j.xphs.2020.05.027_bib46","first-page":"3489","article-title":"Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate\/nanoparticulate powders for pulmonary inhalation aerosol delivery","volume":"8","author":"Duan","year":"2013","journal-title":"Int J Nanomedicine"},{"issue":"5","key":"10.1016\/j.xphs.2020.05.027_bib47","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","volume":"25","author":"Vehring","year":"2008","journal-title":"Pharm Res"},{"issue":"12","key":"10.1016\/j.xphs.2020.05.027_bib48","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.5012\/bkcs.2006.27.12.2002","article-title":"Quenching of ofloxacin and flumequine fluorescence by divalent transition metal cations","volume":"27","author":"Park","year":"2006","journal-title":"Bull Korean Chem Soc"},{"issue":"2","key":"10.1016\/j.xphs.2020.05.027_bib49","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ijpharm.2012.05.045","article-title":"Development of a spray-drying method for the formulation of respirable microparticles containing ofloxacin \u2013 palladium complex","volume":"440","author":"Palazzo","year":"2013","journal-title":"Int J Pharm"},{"issue":"1","key":"10.1016\/j.xphs.2020.05.027_bib50","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1089\/jamp.2007.0643","article-title":"In\u00a0vitro\/in\u00a0vivo comparisons in pulmonary drug delivery","volume":"21","author":"Newman","year":"2008","journal-title":"J\u00a0Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.xphs.2020.05.027_bib51","series-title":"Inhalation Drug Delivery: Techniques and Products","first-page":"1","article-title":"Inhalation drug delivery","author":"Traini","year":"2013"},{"issue":"2","key":"10.1016\/j.xphs.2020.05.027_bib52","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1189\/jlb.70.2.163","article-title":"Functional heterogeneity in liver and lung macrophages","volume":"70","author":"Laskin","year":"2001","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.xphs.2020.05.027_bib53","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ijpharm.2014.02.030","article-title":"Preparation and characterization of spray-dried powders intended for pulmonary delivery of insulin with regard to the selection of excipients","volume":"465","author":"Razavi Rohani","year":"2014","journal-title":"Int J Pharm"},{"issue":"9","key":"10.1016\/j.xphs.2020.05.027_bib54","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1046\/j.1198-743x.2001.00297.x","article-title":"Comparative in\u00a0vitro activities of five quinolone antibiotics, including gemifloxacin, against clinical isolates","volume":"7","author":"G\u00f6n\u00fcll\u00fc","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"10.1016\/j.xphs.2020.05.027_bib55","first-page":"892","article-title":"Comparative in\u00a0vitro antimicrobial activity of the newly synthesized quinolones WQ-3034 and HSR-903 and other quinolones against Mycobacterium tuberculosis and Mycobacterium avium complex","volume":"48","author":"Ogasawara","year":"2000","journal-title":"Jpn J Chemother"},{"key":"10.1016\/j.xphs.2020.05.027_bib56","series-title":"US 10,231,975 B2. Use of Aerolized Levofloxacin for Treating Cystic Fibrosis","author":"Loutit","year":"2014"},{"issue":"3","key":"10.1016\/j.xphs.2020.05.027_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-018-1280-0","article-title":"Spray-dried PulmoSphereTM formulations for inhalation comprising crystalline drug particles","volume":"20","author":"Weers","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2020.05.027_bib58","series-title":"Bronchitol (Mannitol)","year":"2012"},{"key":"10.1016\/j.xphs.2020.05.027_bib59","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.carbpol.2017.05.020","article-title":"Inhaled hyaluronic acid microparticles extended pulmonary retention and suppressed systemic exposure of a short-acting bronchodilator","volume":"172","author":"Li","year":"2017","journal-title":"Carbohydr Polym"},{"issue":"9","key":"10.1016\/j.xphs.2020.05.027_bib60","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1111\/j.2042-7158.2012.01486.x","article-title":"Engineered PLGA nano- and micro-carriers for pulmonary delivery: challenges and promises","volume":"64","author":"Ungaro","year":"2012","journal-title":"J\u00a0Pharm Pharmacol"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492030304X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002235492030304X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:29:32Z","timestamp":1758360572000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002235492030304X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S002235492030304X"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2020.05.027","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a Carrier-Free Dry Powder Ofloxacin Formulation With Enhanced Aerosolization Properties","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2020.05.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}